Effects of progesterone on mammary carcinogenesis by DMBA applied directly to rat mammae. by Jabara, A. G. et al.
Br. J. Cancer (1979) 40, 268
EFFECTS OF PROGESTERONE ON MAMMARY CARCINOGENESIS
BY DMBA APPLIED DIRECTLY TO RAT MAMMAE
A. G. JABARA*t, G. N. MARKSt, J. E. SUMMEESt AND P. S. ANDERSON+
Fromn the Departments of Veterinary Paraclinical Sciences* and Pathologyt,
University of Melbourne, Parkville, Victoria 3052 and Department of Mathematicst,
Monash University, Clayton, Victoria 3168, Australia
Received 27 February 1979 Accepte(d 12 April 1979
Summary.-The effects and site(s) of action of progesterone on DMBA mammary
carcinogenesis in the rat, when a small dose of the carcinogen was applied directly to
the inguinal mammary gland, were investigated.
No reduction in tumour yield was apparent when progesterone was administered
s.c. for 18 days before dusting DMBA. This finding contrasts with a previously
reported inhibitory effect on carcinogenesis when hormone treatment was followed
by intragastric administration of DMBA.
When progesterone injections were begun either 2 days before or 2 days after direct
application of DMBA, and were continued until the end of the experiment (135 or 195
days) an enhancement in carcinogenesis was observed similar to that previously
demonstrated after gastric intubation of DMBA.
These findings, together with previously reported observations, suggest that
progesterone may exert its inhibitory effect on carcinogenesis by acting at a site
outside the breast, perhaps on the liver. However, it is likely that the hormone acts
directly on the mammary tissue to exert its enhancing effect on tumorigenesis.
PREVIOUS INVESTIGATIONS have shown
that exogenous progesterone (not carcino-
genic per se) significantly reduced the
tumour yield in Sprague-Dawley female
rats when the hormone was administered
for 18 days beginning 25 days before feed-
ing a single dose of 7,12-dimethylbenz(a)
anthracene (Jabara et al., 1973). In con-
trast, when daily progesterone injections
were begun either 2 days before or 2 days
after feeding DMBA and were continued
until the end ofthe experiment (135 or 195
days), a significant enhancement in mam-
mary carcinogenesis was obtained (Jabara
& Harcourt, 1970; Jabara et al., 1973).
No insight was gained from the above
investigations as to the site(s) of action of
these contrasting progesterone regimes,
i.e. whether the hormone acted at the level
of the mammary gland or elsewhere. The
present experiments were designed to
investigate this question.
MATERIALS AND METHODS
One hundred and forty non-inbred Sprague-
Dawley virgin female rats were divided
randomly into 7 groups of 20 rats each
(Table I). They were housed 5 animals/cage
and fed commercial pellets and water ad
libitum. At 50 days of age each rat in Groups
2-7 (Table I) had its surgically exposed right
4th mammary gland "dusted" with 2 mg of
powder containing a DMBA-cholesterol mix-
ture (1:1) using the technique described by
Sinha & Dao (1974). The inguinal mammary
glands in the 50-day-old control rats (Group
1) were dusted with 2 mg of cholesterol
powder only. Each animal in Groups 3, 4, 6
and 7 also received s.c. injections of 3 mg of
progesterone (Sigma Chemical Co., U.S.A.)
dissolved in 0-1 ml of corn oil/day 3 times a
week. In Groups 3 and 6 progesterone in-
jections were begun 25 days before DMBA
administration (i.e. on their 25th day of age)
and were continued for 18 days (DMBA+
P-25 to -7). In Group 4 hormone injections
were begun 2 days after DMBA (i.e. on theirPROGESTERONE AND DMIBA MAMMARY CARCINOGENESIS
52nd day of age) and were continued to the
end ofthe experiment, i.e. 135 days (DMBA+
P+2 to + 135), while in Group 7 progesterone
injections commenced 2 days before dusting
DMBA (i.e. on their 48th day of age) and
were continued for 197 days (DMBA+P-2
to +195).
Beginning 4 weeks after DMBA adminis-
tration, all rats were palpated weekly and any
mammary tumour recorded, measured and
graphed as described previously (Jabara,
1967). At autopsy, mammary neoplasms were
removed, fixed in 10% buffered formalin and
5jum paraffin sections were stained with
haematoxylin and eosin.
In the statistical analysis of the results,
'tumour incidence" and "latent periods"
were analysed by means of the log rank test
(Peto & Pike, 1973) and the "tumour growth
behaviour" data were analysed using standard
2 x 2 contingency tables.
RESULTS
In Groups 1-4 only 4 rats (2 in Group 2
and 2 in Group 3) failed to survive to the
end of the experiment (I135 days after
dusting DMBA), all 4 dying from pneu-
monia. In the longer-term groups (5-7),
Total rats
Suirvivors at 28 (lays
at 1,35 (lays
at 195 (lays
No. of rats with mammary car
(O)
Average latent period (days)t
(ranige)
Grow th behaviour of carciniom.
No. growing continuiouisly
No. remainiing static
No. regressing
No. unclassified+
as
considerably fewer animals survived the
total experimental period of 195 days
post-DMBA dusting (Table I) mainly
because many rats had to be killed
earlier because their tumours became
large, ulcerated andinvadedtheabdominal
wall, and sometimes extensively infiltrated
the abdominal contents as well, causing
cachexia of the host. In addition, 2, 3 and
2 rats in Groups 5-7, respectively, died
from pneumonia.
Tumnour incidence and latent periods
Tumours developed only in the inguinal
mammary glands where the DMBA was
applied. In the 3 longer-term groups (5-7)
the majority of rats (29/51) which de-
veloped mammary carcinomas also de-
veloped "non-mammary" neoplasms of
the skin or body wall at the site ofdusting
(Table II). For each ofthe rats developing
both types of neoplasm, it was impossible
to determine to which tumour type the
observed latent period and growth be-
haviour related. The data from the re-
maining animals in Groups 5-7 were there-
fore of little statistical use because of the
3 4 9 1 1
9 8 3 1
0 0 0
0) 0 :3 5
4
DMBA
+
P+2 to
+ 135
20
20
20
5 6
DAMBA I)MBA
+
P-25
to -7
20
20
20
20
I 1
0
5
7
DAIBA
+
P-2 to
+ 195
20
20
14 1 10
15 17 18 16
(75) (85) (90) (80)
80 98 88 68
(63-104) (61-149) (36-155) (40-112)
10
0
0
6
* Twenit.y rats were allocate(d to this grotlp, but 3 clie(d before receiving DAIBA and were therefore
eliminate(d fiom all subsequent calculations and analyses.
t Average based on 10, 7, 9, 6, 7 andl 6 rats in Groups 2-7, respectively.
I Classification was impossible as either no obvious distinction in size was apparent between the initial
granuloma and the tumour which developed subsequently or, in the case of some combined neoplasms, it was
impossible to (letermine wAhether growth was mainly related to the mammary neoplasm or to the tumour
arising from the bo(ly wall or both.
TABLE I. Effects of progesterone (P) on mammary tumour yield when the hormone was
injected daily into rats either before or after dusting DIMBA directly on the right 4th
mnammary gland
Grouip: 1 2 3
Treatment: Chol- DAIBA Dl)IBA
esterol +
P-25
to -7
2) 20 17*
2( 20 17
20) 18 15
cimnomas 0 12 12
(60) (71)
0) 1 10 102
(77-126) (89-118)
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TABLE II. Proportions ofhistological tumour types arising at the site ofDMBA dusting
Tumour type
Experiment,
duration MIC +
Group (days) MC Non-MIC Non-AC *
2 135 t1 1 2 ()
3 ,, 12 0 0 0
4 12 3 2 0
5 195 7 10 2 1
6 9 9 0 0
7 ,, 6 10 2 0
MC= Mammary carcinoma.
Non-MC =Non-mammary tumour.
* Tumour classification impossible as the rat (ied and w,as caninibalizedt.
small number of mammary carcinomas
which arose alone and the biases caused
by the censoring. For this reason only
trends will be reported for these 3 groups.
In Groups 1-4, the shorter duration
produced a greatly decreased incidence of
"non-mammary" tumours, and of the 39
rats which developed mammary carcin-
omas (Groups 2-4) only 4 developed
neoplasms of the body wall or skin as well
(Table II). These 4 animals were elimin-
ated from the statistical analysis of latent
period.
When the rats were first palpated 4
weeks after dusting DMBA, a very small
lump was palpable in the dusted gland in
every animal except those in Group 1,
which were dusted with cholesterol powder
only. These lumps consisted of a granulo-
matous reaction, presumably due to the
DMBA, as it did not occur when only
cholesterol was present, and the tumour
latent period was therefore measured from
the time of dusting DMBA until the lump
began to grow. However, in each of 1, 5
and 3 rats in Groups 2-4, respectively, the
lump palpated at 4 weeks did not vary
appreciably in size throughout the re-
mainder of the experiment, though histo-
logical examination at autopsy revealed it
to be a mammary adenocarcinoma. A
latent period could not be determined in
these 9 rats and therefore they were
eliminated from the statistical analysis.
The dusting vehicle, cholesterol, was not
carcinogenic per se, as shown by the
absence of a tumour in all rats in Group 1
(Table I).
The mammary-cancer incidence and
average tumour latent period in rats in
Group 2, treated only with DMBA, were
not significantly different from those in
Group 3 which had also received pro-
gesterone before the carcinogen (Table I).
However, in Group 4, where progesterone
was administered after DMBA, the log
rank test showed a significantly higher
incidence of mammary carcinomas and
shorter latent period than in Groups 2 and
3 combined (P < 0 05) (Table I).
In the longer-term groups (5-7) it was
not possible to test for differences in
tumour incidence or length of latent
period for the reasons outlined above.
There appeared, however, to be no sub-
stantial difference between the mammary-
cancer incidences in the 3 groups (Table 1).
As seen in the shorter-term group (4),
progesterone treatment after DMBA
appeared to shorten markedly the average
tumour latent period (Group 7) compared
with that in Groups 5 or 6, whilst pro-.
gesterone treatment before DMBA dusting
(Group 6) produced the same induction
time as in the controls (Group 5) (Table I).
Tumour growth behaviour and tumour size
Preliminary examination of the data
relating to the growth behaviour of the
mammary carcinomas which arose in
Groups 2-4 suggested that progesterone
treatment before DMBA dusting (Group 3)
made no difference to neoplastic growth
behaviour compared with that in the con-
trols (Group 2), whilst progesterone treat-
menit after DMBA appeared to stimulate
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many mor-e carcinioimas to glow con-
tinuously. This effect is highly significant
statistically since, after pooling (Groups 2
anid 3 and neglecting the 3 tunclassified
carcinomas in Grouip 4, the stan(lard 2 x 2
contingency table gave a x2 of (6 I8 which
is significant at the 1 00, level.
Whilst tumour size is related to tumour
growth behaviour, it is noteworthy that at
autopsy 53% of the neoplasms in Group 4
(8/15) had obtained an average size of
2 cm or larger, comparedc with onlyr 25°
in Group 3 (3/12) and 8% in CGroup 2
(1/12).
Types oftiunours
All mammary carciionias which arose
in Groups 2-7 (Table I) wTere adeno-
carcinomas, mainly of the papillarv cystic
variety (Jabara, 1967) and progesterone
did not seem to influence either their
macroscopic or microscopic appearances,
regardless of whether the hormone was
administeredbeforeorafterDMBAdusting.
One rat in (Group 4, in addition to the 1 2
animals bearing malignant mammary
growtihs, (leveloped a benign mammary
adenoma (Jabara, 1967) in the duisted
gland, while in the longer-term groups, a
fibroadenoma co-existing with a mammary
adenocarcinoma was seen in 1 rat in
Group 5, 2 in (G'roup 6 anid 3 in Group 7. In
addition, 2 rats in G:roup 7 developed only
a fibroadenoma in the dusted gland.
Non-mammarv neoplasms dcerived from
the skin or body NA-all also developed at the
site of dusting in some rats (Table II).
These tumours sometimes arose alone, btit
more commonly co-existed with mam-
mary growths (Table II). Histologicallv,
most of these other tumours wAere fibro-
sarcomas, a few were rhabdomyosarcomas
or mixed-cell sarcomas and one was a
squamous-cell carcinoma.
D)ISCUSSION
From recent studies it appears that
DMBA reqtuires metabolic activation to
its carcinogenic form (Feuer & Kellen,
1974a, b; De Pierre & Ernster, 1978).
Hence, induction of breast carcinomas
after direct application of DMBA to the
mammary gland indicates that the breast
tissue contains the necessary enzymes to
activate DMBA, as direct application of
such a small dose (1 mg) of carcinogen
appears to eliminate any systemic effect.
This was evidenced by the fact, that
tumours arose only in the mammary
gland that had been dusted with carcino-
gen and, further, that no rat died from
adrenal apoplexy and the adrenal glands
removed at autopsy showed Ino histological
evidence of cortical damage, a common
finding after intragastric administration
of DMBA (Huggins & Morii, 1961; Cefis &
G(oodall, 1963).
The present experiment also showed
that the inhibitory effect of progesterone
pretreatment on DMBA mammary car-
cinogenesis (Jabara et al., 1 973) is abolish-
ed when the carcinogen is applied directly
to the mammary gland, whether the
animals survived for 135 or 195 days. On
the other hand, an enhancing effect of
progesterone on DMBA mammary car-
cinogenesis was still found after direct
application of the carcinogen, similar to
that previously found after gastric intuba-
tion ofDMBA (Jabara, 1967; Jabara et al.,
1973).
These differing effects of progesterone
on DMBA carcinogenesis suggest that the
hormone may be acting at two distinct
sites. In the case of carcinogenic enhance-
ment by progesterone, it is suggested that
the hormone acts directly on the mam-
mary gland to stimulate growth of pre-
existing tumours or malignantly trans-
formed cells. This would explain the
greater number of continuously growing
carcinomas in Groups 4 and 7 than in the
controls, the fact that many more neo-
plasms attained a much larger size in these
2 groups, and the observation that the
appearance of benign mammary tumours,
as well as malignant ones, tended to be
hastened by post-DMBA treatment with
progesterone. The last finding was especi-
ally obvious in the longer-term group (7),
the benign tumours appearing either alone
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or co-existing with a mammary carcinoma.
A similar hastening effect on tumours had
been found when progesterone was ad-
ministered after gastric intubation of the
carcinogen (Jabara, 1967; Jabara et al.,
1973).
Several hypotheses have been advanced
to explain the inhibitory effect of pro-
gesterone on DMBA mammary carcino-
genesis when hormone treatment precedes
carcinogen administration. WAelsch et al.
(1968) suggested that progesterone-in-
duced mammary lobular-alveolar develop-
ment close to the time of DMBA adminis-
tration rendered the gland relatively
refractory to carcinogen action. This view,
however, appears to be invalidated by the
present finding that the inhibitory effect
of progesterone on carcinogenesis was
eliminated when a small dose of DMBA
was applied directly to the mammary
gland.
Dao (1971) on the other hand, mindful
ofthe steric similarity between DMBA and
steroid hormones, proposed that the
presence of excessive amounts of steroid
hormone at receptor sites in mammary
epithelial cells may block the interaction
between DMBA and these sites and hence
inhibit the induction of mammary carcin-
omas. It was observed previously that the
greatest depression in carcinogenesis
occurred when progesterone treatment
was stopped 7 days before feeding DMBA
(Jabara et al., 1973) and this was the
hormone regime adopted in the present
study. However, it was also previously
observed that it took about 10 days from
cessation of progesterone injections before
the rats beganto cyclenormally, indicating
that time is required for the subcutaneous
hormone depot to be totally absorbed,
metabolized and excreted (Jabara et al.,
1972) and hence progesterone must still
have been present when the carcinogen
was administered 7 days after hormone
injections ceased. Therefore, Dao's (1971)
view might be correct, but if so, why did
direct application of DMBA eliminate the
inhibitory effect of progesterone? The
reason may be related to the amount of
DMBA dusted, I mg perhaps being a
relatively large dose of carcinogen to
reach the mammary gland. Most investi-
gators have reported between about 16
and 37 jug of DMBA/g wet weight of
mammary gland homogenate within the
first 24 h offeeding 20-30 mg ofcarcinogen
(Bock & Dao, 1961; Gammal et al., 1965;
Flesher, 1967; Dao et al., 1968). It seems
possible, therefore, that a dose of 1 mg
DMBA may have "swamped" the mam-
mary epithelial-cell steroid receptors, so
abolishing the inhibitory effect of prior
treatment with progesterone.
On the other hand, possibly a more
likely explanation for the abolition of the
inhibitory effect of progesterone pre-
treatment in the present experiment may
be that the hormone acts at a site other
than the breast tissue itself, perhaps on
the liver. When DMBA is fed by stomach
tube it is principally metabolized in the
liver (Feuer & Kellen, 1974a, b). Therefore,
if progesterone were to modify the hepatic
metabolism of DMBA so that more
carcinogen was converted into inactive
metabolites, less DMBA wouldbeavailable
to reach the target tissue and the cancer
incidence would be expected to decrease.
Minasian (1976) fed [3H]DMBA to rats
which had been pretreated with pro-
gesterone for 18 days and observed a 5000
reduction in total radioactivity per mg
protein in isolated mammary epithelial
cells compared with that in the same cells
derived from control rats treated only
with DMBA; the ratio between metab-
olized and unmetabolized DMBA was
similar in both groups. This finding
appears to support the proposal that
progesterone may be acting on the liver.
However, as the level of DMBA in the
plasma was not determined, Dao's (1971)
hypothesis cannot be ruled out.
Feuer & Kellen (1974b) have also sug-
gested that progesterone exerts its effect
on DMBA carcinogenesis through its
action on the liver. They found that in-
duction of pregnancy (a progestational
state) before DMBA administration sig-
nificantly reduced the mammary tumour
272PROGESTERONE AND DMBA MAMMARY CARCINOGENESIS 273
incidence. However, they also observed
that pregnancy reduced hepatic drug
metabolism, as assessed by measurements
of coumarin 3-hydroxylase and glucose
6-phosphatase activities in Sprague-
Dawley rats. It is much more difficult to
reconcile reduced, rather than increased,
hepatic microsomal activity with de-
creased mammary cancer induction, and
further investigations are being carried
out in this laboratory to try to resolve the
controversy.
This work was carried out during the tenure of a
grant from the Anti-Cancer Council of Victoria to
one of us (A.G.J.).
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